Analysts See $-0.11 EPS for DelMar Pharmaceuticals, Inc. (DMPI)

September 8, 2018 - By Palma Niemeyer

DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) Logo

Analysts expect DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) to report $-0.11 EPS on September, 26.They anticipate $0.09 EPS change or 45.00 % from last quarter’s $-0.2 EPS. After having $-0.13 EPS previously, DelMar Pharmaceuticals, Inc.’s analysts see -15.38 % EPS growth. The stock increased 3.62% or $0.019577 during the last trading session, reaching $0.559703. About 151,697 shares traded. DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) has declined 59.35% since September 8, 2017 and is downtrending. It has underperformed by 71.92% the S&P500.

DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. The company has market cap of $12.32 million. The Company’s product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which has completed Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-cancer activity in patients with glioblastoma multiforme, a form of brain cancer. It currently has negative earnings. The firm has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the manufacture and sale of VAL-083 in China; collaboration agreement with the University of Texas MD Anderson Cancer Center; and collaboration agreement with Accurexa Inc. to develop a novel formulation for the local delivery of combination chemotherapy for the treatment of brain cancer and other solid tumors.

Another recent and important DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) news was published by which published an article titled: “The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut” on August 14, 2018.

DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.